ARDELYX INC. - COMMON STOCK

Ardelyx, Inc. Reports Employment Inducement Grants

23 May 2023 15:05:00 By Nasdaq GlobeNewswire

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

17 May 2023 06:30:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

15 May 2023 15:05:01 By Nasdaq GlobeNewswire

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

09 May 2023 07:00:02 By Nasdaq GlobeNewswire

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

03 May 2023 15:02:00 By Nasdaq GlobeNewswire

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

01 May 2023 07:00:01 By Nasdaq GlobeNewswire

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

26 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

13 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

12 Apr 2023 15:05:50 By Nasdaq GlobeNewswire

Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

02 Mar 2023 15:02:00 By Nasdaq GlobeNewswire

Ardelyx Publishes First Environmental, Social and Governance (ESG) Report

28 Feb 2023 07:00:03 By Nasdaq GlobeNewswire

Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference

27 Feb 2023 07:15:00 By Nasdaq GlobeNewswire

Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023

23 Feb 2023 07:00:01 By Nasdaq GlobeNewswire